Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)
8-K/A - Tevogen Bio Holdings Inc. (0001860871) (Filer)
8-A12B - Semper Paratus Acquisition Corp (0001860871) (Filer)
Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for large patient populations. WARREN, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen Bio"), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology, has announced the completion of Tevogen Bio Inc's previously announced business combination with Semper Paratus Acquisition Corporation, leading to the formation of Tevogen Bio Holdings Inc. The combined company's common s
New York, NY, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation ("Semper Paratus") (NASDAQ:LGST, LGSTW, LGSTU))), a publicly-traded special purpose acquisition company, announced today that its shareholders have approved the proposed business combination (the "Business Combination") with Tevogen Bio Inc, a Delaware corporation ("Tevogen Bio"), at an extraordinary general meeting of Semper Paratus' shareholders that was held on Wednesday, January 31, 2024 (the "Meeting"). Each of the proposals presented at the Meeting was approved, and the Business Combination is expected to be consummated as soon as practicable following the satisfaction or waiver of the remaining c
New York, NY, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Semper Paratus Acquisition Corporation ("Semper Paratus") (NASDAQ:LGST, LGSTW))), a publicly-traded special purpose acquisition company, today announced that it has filed a supplement ("Prospectus Supplement") to its definitive proxy statement/prospectus dated January 10, 2024 (the "Proxy Statement/Prospectus") for the solicitation of proxies in connection with the extraordinary general meeting of Semper Paratus' shareholders scheduled to be held on January 29, 2024, to consider and vote on, among other proposals as more fully set forth in the Proxy Statement/Prospectus, the transactions (collectively, the "Business Combination") contemplated
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
4 - Tevogen Bio Holdings Inc. (0001860871) (Issuer)
SC 13D - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13D - Tevogen Bio Holdings Inc. (0001860871) (Subject)
SC 13G/A - Semper Paratus Acquisition Corp (0001860871) (Subject)